Comparative Pharmacology
Head-to-head clinical analysis: PORCINE SECRETIN versus THYROGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORCINE SECRETIN versus THYROGEN.
PORCINE SECRETIN vs THYROGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
Recombinant human thyroid-stimulating hormone (TSH) that binds to TSH receptors on thyroid follicular cells, stimulating iodine uptake, thyroglobulin synthesis, and release of thyroid hormones.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
0.9 mg intramuscular injection every 24 hours for 2 doses, or 1.2 mg orally as a single dose.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
12-15 hours (terminal elimination half-life in patients with normal renal function; may be prolonged in renal impairment). Clinically, TSH levels peak by 3 hours after IM injection and return to baseline by 24-48 hours.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Primarily renal (thyrotropin is a glycoprotein hormone; intact hormone is minimally excreted unchanged; metabolic degradation products are eliminated renally). After IV administration, approximately 96% of the dose is recovered in urine within 24 hours as low molecular weight degradation products. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent